Table 3.
Demographic and clinical characteristics of anakinra vs. no anakinra groups before and after propensity score matching
| Before propensity score matching | After propensity score matching | |||||
|---|---|---|---|---|---|---|
| Demographics | Anakinra (N = 57) |
No Anakinra (N = 52) | p value | Anakinra (N = 31) |
No Anakinra (N = 31) | p value |
| Age (years), median (IQR) | 9.9 (8.1–13.9) | 9.4 (7.2–11.7) | 0.13 | 8.8 (5.8–12.9) | 9.5 (7.8–11.4) | 0.89 |
| Female, n (%) | 25 (44) | 24 (46) | 0.8 | 14 (45) | 15 (48) | 0.8 |
| Race/Ethnicity, n (%) | 0.67 | 0.26 | ||||
| Asian | 1 (2) | 2 (4) | 0 (0) | 1 (3) | ||
| White non-Hispanic | 8 (14) | 12 (23) | 7 (23) | 10 (32) | ||
| Hispanic | 23 (40) | 20 (38) | 16 (52) | 9 (29) | ||
| Black non-Hispanic | 22 (39) | 15 (29) | 8 (26) | 10 (32) | ||
| Comorbidities, n (%) | 28 (49) | 19 (37) | 0.18 | 15 (48) | 11 (35) | 0.3 |
| Asthma | 9 (16) | 8 (15) | 1 | 3 (10) | 5 (16) | 0.71 |
| Obesity | 9 (16) | 5 (10) | 0.39 | 3 (10) | 3 (10) | 1 |
| Clinical Characteristics (at presentation) | ||||||
| Temperature ( o C) | ||||||
| Temperature, median (IQR) | 38.9 (38.2–39.6) | 39.1 (38.3–39.5) | 0.2 | 39.0 (38.3–39.7) | 38.9 (38.2–39.5) | 0.98 |
| Presence of fever, n (%) | 56 (98) | 50 (96) | 0.73 | 25 (80) | 26 (84) | 0.73 |
| Laboratory markers, median (IQR) | ||||||
| CRP (mg/dL) | 18.6 (14-22.5) | 14.2 (9.6–21.4) | 0.07 | 16.4 (12.8–21.7) | 19.0 (12.7–24.1) | 0.43 |
| High sensitivity troponin (pg/mL) | 129.5 (14.7–273) | 27.4 (2.5–97.1) | 0.002 | 14.7 (3.1–60.9) | 27.4 (2.5–99.0) | 0.98 |
| Creatinine (mg/dL) | 0.6 (0.4-1.0) | 0.5 (0.4–0.8) | 0.35 | 0.57 (0.42–0.74) | 0.60 (0.47–0.91) | 0.66 |
| ALT (units/L) | 43 (19–65) | 29 (18–65) | 0.43 | 45 (20–73) | 30 (20–75) | 0.74 |
| D-dimer (mcg/mL FEU) | 3.4 (2.3–6.1) | 2.7 (1.5–4.2) | 0.06 | 3.2 (2.4–5.6) | 2.7 (2.0-4.9) | 0.32 |
| Ferritin (ng/ml) | 482 (280–1166) | 333 (191–978) | 0.05 | 525 (354–1193) | 584 (239–1026) | 0.69 |
| Severe classification, n (%) | 49 (86) | 26 (50) | 0.00005 | 24 (77) | 24 (77) | 1 |
| Immunomodulatory treatment, median (IQR) | ||||||
| Time to IVIG (hours) | 12.1 (8.9–22.5) | 18.4 (10.9–30.6) | 0.03 | 14.1 (9.9–32.4) | 17.6 (9.7–23.2) | 0.94 |
| Time to steroids (hours) | 11.5 (6.5–20.5) | 18.5 (8.1–32.7) | 0.03 | 12.9 (7.7–25.3) | 15.8 (7.8–28.7) | 0.69 |
| Time to anakinra (hours) | 23.8 (14.6–37.9) | NA | NA | 26.1 (14.6–56.8) | NA | NA |
|
Anakinra duration (days) Time from last anakinra |
5.5 (3.3–5.8) | NA | NA | 4.9 (3.8–7.2) | NA | NA |
| dose to discharge (hours) | 47.4 (28.0–59.0) | NA | NA | 47.4 (25.9–58.7) | NA | NA |